Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE186960 | Panc1 cell line | Cell line | Pancreatic cancer | Pancreatic ductal adenocarcinoma (PDAC) | Chemotherapy | gemcitabine | NA | Malignant cells | 0.661659 | 0.00e+00 |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | post | Mono/Macro | -0.292899 | 2.43e-14 |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | Mono/Macro | -0.397573 | 2.26e-11 |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | B cells | 0.401964 | 2.31e-08 |
GSE153697 | patients | Bone marrow aspirate | Acute lymphoblastic leukemia | Relapsed B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | anti-CD19 CAR-T | NA | Malignant cells | 0.573085 | 2.20e-39 |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | post | Plasma cells | -0.454533 | 8.87e-09 |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre | Mono/Macro | 0.505093 | 5.29e-37 |
GSE189460 | patients | Bone marrow aspirate | Multiple myeloma | Multiple myeloma (MM) | Targeted therapy | bortezomib + melphalan + prednisolone | pre | Malignant cells | 0.596838 | 0.00e+00 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | post | Malignant cells | -0.674431 | 6.20e-36 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | pre | Malignant cells | -0.417621 | 8.40e-31 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post | cDCs | 0.326301 | 2.22e-08 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | pre | Malignant cells | -0.390118 | 0.00e+00 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | B cells | 0.305652 | 1.32e-07 |
GSE115251 | Kelly cell line | Cell line | Neuroblastoma | Neuroblastoma | Targeted therapy | TAE684 | NA | Malignant cells | -0.32876 | 0.00e+00 |
Gene symbol | motif | TF_highConf |
MEF2C | transfac_pro__M06404 | ZNF497 (directAnnotation). |
MEF2C | metacluster_196.2 | MECOM; NR2C1; NR2C1; PPARD; PPARD; PRDM16; RARA; RARA; RARB; RARB; RARG; RARG; RORB; RORB; RORC; RORC; RUNX1; RXRA; RXRA; RXRB; RXRB; RXRG; RXRG; RXRG; RXRG; THRB; THRB (directAnnotation). RXRA (inferredBy_Orthology). |
MEF2C | jaspar__MA1563.2 | SOX18 (directAnnotation). |
MEF2C | transfac_pro__M06830 | ZNF528 (directAnnotation). |
MEF2C | transfac_pro__M05717 | ZNF134; ZNF154; ZNF256; ZNF304; ZNF418; ZNF419; ZNF480; ZNF548; ZNF549; ZNF552; ZNF561; ZNF562; ZNF584; ZNF586; ZNF587B; ZNF610; ZNF772; ZNF773; ZNF792; ZNF793; ZNF837 (inferredBy_Orthology). |
MEF2C | transfac_pro__M06253 | ZSCAN2 (inferredBy_Orthology). |
MEF2C | taipale_tf_pairs__ETV2_DLX2_RCCGGAANNNNNNYAATTA_CAP_repr | DLX2; ETV2 (directAnnotation). |
MEF2C | transfac_pro__M02830 | ZSCAN26 (inferredBy_Orthology). |
MEF2C | transfac_pro__M06130 | ZNF254 (directAnnotation). |
MEF2C | taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr | CREB1 (directAnnotation). |
MEF2C | taipale_cyt_meth__CREB1_NRTGAYGCGTN_eDBD_meth_repr | CREB1 (directAnnotation). |
MEF2C | taipale_cyt_meth__HSF5_AACRTTCTAGAAYGYT_eDBD_meth | HSF5 (directAnnotation). |
MEF2C | transfac_public__M00285 | NFE2L1 (directAnnotation). |
MEF2C | taipale_tf_pairs__ELK1_FOXI1_RSCGGAANNRTMAAYAN_CAP_repr | ELK1; FOXI1 (directAnnotation). |
MEF2C | taipale_cyt_meth__JUND_NRTGACGCATN_eDBD_repr | JUND (directAnnotation). |
MEF2C | metacluster_111.5 | E4F1; E4F1 (directAnnotation). |
MEF2C | transfac_pro__M05640 | ZNF735 (directAnnotation). |
MEF2C | tfdimers__MD00036 | FOS; FOSB; FOSL1; FOSL2; ILF2; JUN; JUNB; JUND; NFATC2 (directAnnotation). |
MEF2C | transfac_pro__M01251 | E2F1 (directAnnotation). |
MEF2C | taipale__Esrra_DBD_TTCAAGGTCAN_repr | ESRRA (inferredBy_Orthology). |
MEF2C | transfac_pro__M05762 | ZNF774 (directAnnotation). |
MEF2C | transfac_pro__M06611 | ZNF560 (directAnnotation). |
MEF2C | tfdimers__MD00321 | FLI1; ING4 (directAnnotation). |
MEF2C | metacluster_126.2 | ZBTB4; ZBTB4 (directAnnotation). |
MEF2C | metacluster_67.2 | ZNF501 (directAnnotation). ACAA1; E2F2; E2F2; E2F3; E2F3; FOXN4 (inferredBy_Orthology). |
MEF2C | taipale_tf_pairs__ETV5_HES7_CCGGAANNNNNNCACGTG_CAP | ETV5; HES7 (directAnnotation). |
MEF2C | transfac_pro__M08894 | OVOL1; OVOL2 (directAnnotation). |
MEF2C | transfac_pro__M02089 | E2F3 (directAnnotation). |
MEF2C | metacluster_19.9 | AHR; AHR; SREBF1; SREBF1; SREBF2; SREBF2 (directAnnotation). SREBF1 (inferredBy_Orthology). |
MEF2C | taipale_cyt_meth__GCM1_RTGCGGGTN_eDBD | GCM1 (directAnnotation). |
MEF2C | cisbp__M00809 | PRDM11 (inferredBy_Orthology). |
MEF2C | hdpi__NRL | NRL (directAnnotation). |
MEF2C | transfac_pro__M02898 | SMAD3 (directAnnotation). |
MEF2C | transfac_pro__M02933 | ZBTB14 (inferredBy_Orthology). |
MEF2C | kznf__EGR2_Barrera2016.1_PBM | EGR2 (directAnnotation). |
MEF2C | metacluster_15.2 | E2F1; E2F1; E2F1; E2F1; E2F1; E2F3; E2F4; E2F4; E2F4; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F7; TFDP1; TFDP2; ZNF566; ZNF566; ZNF574 (directAnnotation). E2F3; E2F3; E2F4 (inferredBy_Orthology). |
MEF2C | hdpi__HIP2 | UBE2K (directAnnotation). |
MEF2C | transfac_pro__M00430 | E2F1 (directAnnotation). |
MEF2C | homer__NANTGCSGCA_Zfp57 | ZFP57 (directAnnotation). |
MEF2C | transfac_pro__M07329 | SP7 (directAnnotation). |
MEF2C | metacluster_197.3 | E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F2; E2F2; E2F2; E2F2; E2F2; E2F3; E2F3; E2F3; E2F3; E2F3; E2F3; E2F3; E2F4; E2F4; E2F4; E2F4; E2F4; E2F4; E2F4; E2F4; E2F4; E2F4; E2F5; E2F5; E2F5; E2F5; E2F6; E2F7; E2F7; E2F7; RB1; TFDP1; TFDP1; TFDP1; TFDP1; TFDP1; TFDP1; TFDP1; TFDP2; TFDP2 (directAnnotation). |
MEF2C | cisbp__M07938 | E2F1 (directAnnotation). |
MEF2C | metacluster_15.3 | E2F1; E2F6; E2F8; E2F8; TFDP1 (directAnnotation). E2F3 (inferredBy_Orthology). |
MEF2C | hocomoco__EGR4_HUMAN.H11MO.0.D | EGR4 (directAnnotation). |
MEF2C | metacluster_3.7 | SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP3; SP3; SP3; SP4; SP4; SP4; SP4; SP4; SP4; SP5 (directAnnotation). |
MEF2C | transfac_pro__M07436 | WT1 (directAnnotation). |
MEF2C | transfac_pro__M01090 | SMAD9 (inferredBy_Orthology). |
MEF2C | transfac_pro__M01837 | KLF11 (directAnnotation). |
MEF2C | transfac_pro__M02844 | BCL6B (inferredBy_Orthology). |
MEF2C | transfac_pro__M07310 | SP5 (directAnnotation). |
1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |